Jan Binon
- Specialism: Fractional and interim CFO for MedTech and Biotech, seed to Series B. Fundraising and investor due diligence.
– R&D tax credits and grant funding.
– COGS and price modelling.
– Business model building.
– Financial modelling and valuation.
– Cash and burn management.
– Finance function establishment and build-out
– Institutional-grade board reporting
– M&A and post-acquisition integration, including into NASDAQ-listed parents.
– US, EU and UK compliance. - Track Record: MRM Health, Idevax and CareForMe (current and recent). Novosanis, acquired by NASDAQ-listed OraSure Technologies. Earlier: PerkinElmer (Euroscreen Products integration), Duracell through its carve-out from Procter & Gamble to Berkshire Hathaway, Cabot, Crestron, and the King Baudouin Foundation.
- Offer: First and foremost I am a partner to founders and CEOs, and the critical voice in the room that makes them drive better decisions. I co-build the business model with them and translate it into the financials they use to raise from the right investors. After the raise I establish the governance and institutional-grade board reporting a serious board expects, and keep the cash and burn honest. I have seen how the movie ends at some of the largest companies in the world, including post-acquisition integrations into US-listed parents, and I bring that to start-ups and scale-ups in MedTech and Biotech, from seed to Series B.
- Jan says: “A critical finance mind in the room from early on sharpens every decision you make. The (non-dilutive) funding it tends to unlock is nice too.”
- Try me: linkedin.com/in/jan-binon
I have always worked on projects. Even inside big companies, I gravitated to the project, the integration, the build, the thing with a start and an end and a problem to solve, and I spent time as a project consultant too. So this was never a pivot for me. It is how I have always worked, now applied to founders and companies that affect society. What drives me is curiosity and impact. I learned as much about finance, project work and corporate life as I could because I wanted to understand how these things actually work, and then use that understanding where it makes the most difference.
The job I enjoyed most, looking back, was integrating Euroscreen Products into PerkinElmer. It combined impactful science with genuinely hands-on building. From there, I followed my curiosity, combining it with societal impact where possible. I designed the reporting model and led the initial ERP implementation at the King Baudouin Foundation, which they still use. I kept taking on the project rather than the title. My last large project was integrating the financials of a Belgian medtech company, Novosanis, into a NASDAQ-listed company, OraSure. It was the culmination of everything that came before, with a real sense of impact through work on non-invasive screening. When Belgian operations stopped, I decided to find opportunities where I could contribute the most.
The full integration of Euroscreen Products into PerkinElmer was the first time I saw what I was good at and what I cared about line up: serious science, real hands-on work, and a finance and reporting structure that had to be built, not just maintained. It set the pattern for everything since.
Along the way, I learned how to be a complementary voice in a team’s decision-making, and how to be the finance partner who uses that voice, in dialogue, to help the team reach better decisions. Not the person who hands down the numbers, but the one who improves the thinking around them. I also learned where I want to spend that voice: on finance that contributes to society, not finance for its own sake.
It’s working for me now because it brings together the two things that have always driven me. I get to use finance where it contributes most, with mission-driven companies, and I get to work with many strong, driven founder teams at once. That last part genuinely enriches my world. The Novosanis and OraSure years were the template: a mission-driven healthtech company where I could put all my learnings to work. The non-invasive HPV screening from a first-void urine sample still strikes me as quietly powerful. After that, I knew I wanted to keep contributing where I can add the most value, for companies that affect society.
Looking ahead, I hope for more of the same, really. More partnering with strong founder teams and more work that matters. Ideally, I would like to make a lasting impact on the wider life sciences and healthcare community by helping solutions reach patients and by democratising financial knowledge for founders.